QC
PTCT icon

Quadrature Capital’s PTC Therapeutics PTCT Stock Holding History

Quadrature Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,582
Closed -$468K – 1402
2025
Q2 		$468K Sell
9,582
-3,098
-24% -$147K 0.01% 588
2025
Q1 		$646K Buy
+12,680
New +$633K 0.01% 520

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrature Capital's PTCT Position: Q3 2025 in Review

Quadrature Capital sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 9,582 shares — an estimated $468K sold.

Quadrature Capital first reported a position in PTCT in Q1 2025 and held it in 2 quarters. The position peaked at $646K in Q1 2025. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Quadrature Capital reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quadrature Capital sold 9,582 PTC Therapeutics shares in Q3 2025, an estimated $468K.
  • Quadrature Capital first reported a position in PTC Therapeutics in Q1 2025 and held it in 2 quarters.
  • Quadrature Capital's PTC Therapeutics position peaked at $646K in Q1 2025.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.